Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome ... Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and Hypoplastic left heart syndrome (HLHS). Show more
On-going Phase 2b clinical trial (ELPIS II) deemed pivotal and, if positive, acceptable for Biological License Application (BLA) submission for potential full traditional approvalAlignment with...
MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...
Cisco Systems (NASDAQ:CSCO) – The networking and IT solutions company reported adjusted earnings of 87 cents per share on revenue of $13.64 billion, while analysts surveyed by LSEG expected...
Positive data from the Phase 2a clinical trial (CLEAR MIND ) evaluating Lomecel-B™ in Alzheimer’s disease presented in Featured Research Oral Presentation at Alzheimer’s Association International...
U.S. stock index futures are little changed in pre-market trading on Wednesday after a strong recovery in stocks on Tuesday. The indices surpassed the levels seen on August 2, prior to the global...
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...
– Featured Research Session oral presentation highlights findings that show Lomecel-B™ improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s Disease –...
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular...
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular...
– FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ – – Second designation received for Lomecel-B™ for the treatment of mild Alzheimer’s Disease...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -3 | 2 | 2.24 | 1.92 | 514812 | 2.03072738 | CS |
4 | -0.33 | -14.5374449339 | 2.27 | 2.31 | 1.92 | 505900 | 2.06537211 | CS |
12 | 0.27 | 16.1676646707 | 1.67 | 6.39 | 1.5798 | 4856024 | 3.76654122 | CS |
26 | -2.06 | -51.5 | 4 | 6.39 | 0.7707 | 6437801 | 2.98710842 | CS |
52 | -20.06 | -91.1818181818 | 22 | 26.7 | 0.7707 | 3405879 | 3.50392047 | CS |
156 | -34.96 | -94.7425474255 | 36.9 | 450 | 0.7707 | 2719124 | 94.94654027 | CS |
260 | -12.86 | -86.8918918919 | 14.8 | 450 | 0.7707 | 2116226 | 94.1562379 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.